Overview

GI Dynamics, Inc. Company Overview

GI Dynamics, Inc. (ASX: GID) is the developer of EndoBarrier®, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not available for sale in the U.S. and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts.... More »
GID.AX (CHESS Depository Interests)
A$0.07
0.00 (0.00%)
Stock chart for: GID.AX.  Currently trading at A$0.07 with a 52 week high of A$0.09 and a 52 week low of A$0.02.
Data as of Jun 21, 2017 4:00 p.m.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Refresh quote

Investor Contact

Main:
Janell Shields
investor@gidynamics.com
+1 781-357-3280 (U.S.)

Share Registry

Link Market Services Limited
General Shareholder Enquiries:
Phone: 1300 554 474 (toll free) or +61 2 8280 7111
registrars@linkmarketservices.com.au
Fax: +61 2 9287 0303

Online investor log-in
Locked Bag A14
Sydney South NSW 1235
Australia

Quote is a for a CHESS Depositary Interests (CDI) 1 share of common stock = 50 CDIs